Conference abstractPublished 26 Jun 2013
Design of new leads as novel therapeutics for tuberculosis - A computational approach
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Tuberculosis (TB) has been a global health threat currently affecting 9million new cases every year. In spite of chemotherapy and BCG vaccine, Mycobacterium tuberculosis (MTB) is causing one death in every 10 seconds. Major challenges and lacunae in the existing therapy are: prolonged therapy coupled with poor compliance of patients to drug administration and adaptation of the pathogen to evolve into multidrug resistant (MDR) and extensively drug resistant (XDR) TB strains. In view of the latest technological information about the genome of the MTB and the mechanism of MTB manifestation, novel targets involved in various phases of life cycle of the bacteria may be considered for design of effective TB therapeutics. In the present work, proteins involved in (a) Transcription (b) Dormant stage and (c) Multidrug resistance of MTB, are explored for design of effective leads as antagonists for the mycobacterium pathogen. Computational techniques are applied to the targets, for 3D structural evaluation, identification of active site and novel leads are designed using virtual screening against the active site with molecular databases. Specific examples are presented and discussed. The study identifies new molecular entities for tuberculosis therapy.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biotechnology & Biomaterials
- SubjectBiochemistry & Biotechnology
- SubjectMaterials Science
- BylineArticles whose byline prints “Uma Vuruputuri”
- BylineArticles whose byline prints “Vasavi Malkhed”